Charles L. Crespi

9.9k citations

97 papers · 7.8k indexed · 3 hit papers · h-index 44

Pharmacology top 0.02%
- Pharmacogenetics and Drug Metabolism 61
- Inflammatory mediators and NSAID effects 8
Health, Toxicology and Mutagenesis top 0.5%
- Toxic Organic Pollutants Impact 8
Biochemistry top 0.5%
- Eicosanoids and Hypertension Pharmacology 13
Cancer Research top 1%
- Carcinogens and Genotoxicity Assessment 31
Oncology top 1%
- Drug Transport and Resistance Mechanisms 23
Spectroscopy
- Analytical Chemistry and Chromatography 10
Pharmaceutical Science
- Chemical Reactions and Isotopes 9

Co-authors: Bruce W. Penman Vaughn P. Miller William F. Busby David J. Waxman Frank J. Gonzalez Thomas K. H. Chang Arthur L. Lafleur Harry V. Gelboin
Cited by: Pharmacology Health, Toxicology and Mutagenesis Biochemistry
Journals: Proceedings of the National Academy of Sciences (1 paper)Environmental Science & Technology (4 papers)Analytical Biochemistry (4 papers)
Partner nations: United States Canada United Kingdom

In The Last Decade

Charles L. Crespi

97 papers receiving 7.6k citations

Hit Papers

align trajectories log scale

What are hit papers?

Hit papers significantly outperform the citation benchmark for their cohort. A paper qualifies if it has ≥500 total citations, achieves ≥1.5× the top-1% citation threshold for papers in the same subfield and year (this is the minimum needed to enter the top 1%, not the average within it), or reaches the top citation threshold in at least one of its specific research topics.

1996 Mutation Research/Genetic Toxicology
1993 PubMed
1992 Proceedings of the National Academy of Sciences

Peers

Countries citing papers authored by Charles L. Crespi

Since Specialization

Citations

This map shows the geographic impact of Charles L. Crespi's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Charles L. Crespi with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Charles L. Crespi more than expected).

Fields of papers citing papers by Charles L. Crespi

Since Specialization

Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by Charles L. Crespi. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Charles L. Crespi. The network helps show where Charles L. Crespi may publish in the future.

Co-authorship network

The 25 scholars most cited alongside Charles L. Crespi, linked wherever they have co-authored with each other. Click a name or a connecting line to browse the papers they share.

Border = papers with Charles L. Crespi Line = papers co-authored together Charles L. Crespi links everyone, so they are left out of the graph.

All Works

Sort: Min cites: Since: Top N: Style:

20 of 20 papers shown

#	Work
1	A Multi-Endpoint Evaluation of Cytochrome P450 1A2, 2B6 and 3A4 Induction Response in Human Hepatocyte Cultures After Treatment with β - Naphthoflavone, Phenobarbital and Rifampicin Drug Metabolism Letters ·George Zhang,Thuy Ho,Alanna L. Callendrello,Charles L. Crespi,David M. Stresser	2010	26
2	Differential Time- and NADPH-Dependent Inhibition of CYP2C19 by Enantiomers of Fluoxetine Drug Metabolism and Disposition ·David M. Stresser,Andrew K. Mason,Elke S. Perloff,Thuy Ho,Charles L. Crespi,Andre Dandeneau,Ling Morgan,Shangara S. Dehal	2009	16
3	HUMAN CYTOCHROME P450 INDUCTION AND INHIBITION POTENTIAL OF CLEVIDIPINE AND ITS PRIMARY METABOLITE H152/81 Drug Metabolism and Disposition ·George Zhang,Shangara S. Dehal,Thuy Ho,Jennifer Johnson,Catherine Chandler,Andrew P. Blanchard,R. J. H. Clark,Charles L. Crespi,David M. Stresser,James Wong	2006	34
4	HIGHLY SELECTIVE INHIBITION OF HUMAN CYP3A IN VITRO BY AZAMULIN AND EVIDENCE THAT INHIBITION IS IRREVERSIBLE Drug Metabolism and Disposition ·David M. Stresser,Marc I. Broudy,Thuy Ho,Catherine E. Cargill,Andrew P. Blanchard,Raman Sharma,Andre Dandeneau,Joseph Goodwin,Stephanie D. Turner,John C. L. Erve,Christopher Patten,Shangara S. Dehal,Charles L. Crespi	2004	115
5	High-Performance Liquid Chromatographic Analysis of CYP2CSCatalyzed Paclitaxel 6α-Hydroxylation Humana Press eBooks ·Charles L. Crespi,Thomas K. H. Chang,David J. Waxman	2003	2
6	Spectrophotometric Analysis of Human CY P2El -Catalyzed pNitrophenol Hydroxylation Humana Press eBooks ·Thomas K. H. Chang,Charles L. Crespi,David J. Waxman	2003	56
7	Characterization of Cytochrome P450 2D6.1 (CYP2D6.1), CYP2D6.2, and CYP2D6.17 Activities toward Model CYP2D6 Substrates Dextromethorphan, Bufuralol, and Debrisoquine Drug Metabolism and Disposition ·Kenda Marcucci,Robin E. Pearce,Charles L. Crespi,Dorothy T. Steimel,J. Steven Leeder,Andrea Gaedigk	2002	53
8	Thiourea toxicity in mouse C3H/10T12 cells expressing human flavin-dependent monooxygenase 3 Biochemical Pharmacology ·P.Blaise Smith,Charles L. Crespi	2002	38
9	Effect of Methanol, Ethanol, Dimethyl Sulfoxide, and Acetonitrile on In Vitro Activities of cDNA-Expressed Human Cytochromes P-450 Drug Metabolism and Disposition ·William F. Busby,Joseph M. Ackermann,Charles L. Crespi	1999	245
10	Use of cDNA-Expressed Human Cytochrome P450 Enzymes to Study Potential Drug-Drug Interactions Advances in pharmacology ·Charles L. Crespi,Bruce W. Penman	1997	101
11	Development of a human lymphoblastoid cell line constitutively expressing human CYP1B1 cDNA: substrate specificity with model substrates and promutagens Mutagenesis ·Charles L. Crespi,B. W-Penman,Dorothy T. Steimel,Theresa J. Smith,Chung S. Yang,Thomas R. Sutter	1997	96
12	Human cell mutagenicity of oxygenated, nitrated and unsubstituted polycyclic aromatic hydrocarbons associated with urban aerosolsbreakdown → Mutation Research/Genetic Toxicology ·John L. Durant,William F. Busby,Arthur L. Lafleur,Bruce W. Penman,Charles L. Crespi	1996	713
13	Mutagenicity of benzo[a]pyrene and dibenzopyrenes in the Salmonella typhimurium TM677 and the MCL-5 human cell forward mutation assays Mutation Research/Genetic Toxicology ·William F. Busby,Henrietta Smith,Charles L. Crespi,Bruce W. Penman	1995	67
14	Human cell lines, derived from AHH-1 TK+/− human lymphoblasts, genetically engineered for expression of cytochromes P450 Toxicology ·Charles L. Crespi,Robert Langenbach,Bruce W. Penman	1993	61
15	Recombinant DNA approaches for the development of metabolic systems used in in vitro toxicology Mutation Research/Reviews in Genetic Toxicology ·Robert Langenbach,P.Blaise Smith,Charles L. Crespi	1992	40
16	The development of a human cell line stably expressing human CYP3A4: role in the metabolic activation of aflatoxin B₁ and comparison to CYP1A2 and CYP2A3 Carcinogenesis ·Charles L. Crespi,Bruce W. Penman,Dorothy T. Steimel,Harry V. Gelboin,Frank J. Gonzalez	1991	107
17	A tobacco smoke-derived nitrosamine, 4-(methytnitrosamino)-1-(3-pyridyl)-1-butanone, is activated by multiple human cytocbrome P450s including the polymorphic human cytochrome P4502D6 Carcinogenesis ·Charles L. Crespi,Bruce W. Penman,Harry V. Gelboin,Frank J. Gonzalez	1991	191
18	Stable expression of human cytochrome P450IA2 cDNA in a human lymphoblastoid cell line: Role of the enzyme in the metabolic activation of aflatoxin B₁ Molecular Carcinogenesis ·Charles L. Crespi,Dorothy T. Steimel,Toshifumi Aoyama,Harry V. Gelboin,Frank J. Gonzalez	1990	36
19	Development of a human cell line by selection and drug-metabolizing gene transfection with increased capacity to activate promutagens Carcinogenesis ·Robert L. Davies,Charles L. Crespi,K Rudo,Thomas R. Turner,Robert Langenbach	1989	50
20	The mutagenic activity of selected compounds at the TK locus: Rodent vs. human cells Mutation Research/Reviews in Genetic Toxicology ·William J. Caspary,Robert Langenbach,Bruce W. Penman,Charles L. Crespi,B. Myhr,Ann D. Mitchell	1988	24

About Charles L. Crespi

Charles L. Crespi is a scholar working on Pharmacology, Cancer Research and Biochemistry, having authored 97 papers that have together received 7.8k indexed citations. Recurring topics across this work include Pharmacogenetics and Drug Metabolism (61 papers), Carcinogens and Genotoxicity Assessment (31 papers), Drug Transport and Resistance Mechanisms (23 papers), Eicosanoids and Hypertension Pharmacology (13 papers), Analytical Chemistry and Chromatography (10 papers), Chemical Reactions and Isotopes (9 papers), Toxic Organic Pollutants Impact (8 papers) and Inflammatory mediators and NSAID effects (8 papers). The work is most often cited by research in Pharmacology (3.5k citations), Health, Toxicology and Mutagenesis (1.2k citations) and Biochemistry (605 citations). Charles L. Crespi has collaborated with scholars based in United States, Canada and United Kingdom. Frequent co-authors include Bruce W. Penman, Vaughn P. Miller, William F. Busby, David J. Waxman, Frank J. Gonzalez, Thomas K. H. Chang, Arthur L. Lafleur, Harry V. Gelboin, David M. Stresser and John L. Durant. Their work appears in journals such as Proceedings of the National Academy of Sciences, Environmental Science & Technology and Analytical Biochemistry.

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact